Adult Study to Evaluate Placement of Tympanostomy Tubes In-office (ADEPT)

Tusker Medical

Status and phase

Completed

Phase 2

Conditions

OME - Otitis Media With Effusion

AOM - Acute Otitis Media

Barotrauma;Ear

Eustachian Tube Dysfunction

Treatments

Combination Product: Tymbion Iontophoresis and Tube Delivery System (TDS)

Study type

Interventional

Funder types

Industry

Identifiers

NCT03197558

CPR007003 - Group B

Details and patient eligibility

About

A prospective, multicenter study to evaluate effectiveness and safety of Tymbion iontophoresis and tympanostomy tube placement using the Tula iontophoresis and tube delivery systems for adults in an office setting.

This study cohort is called Group B and includes tube placement. Protocol CPR007003 also included a first study group ('A', without tube placement) that was completed and described in a separate registration (NCT03119181).

Full description

The objective for Group B in the study is to evaluate tolerability and safety of tympanostomy tube (TT) placement in adults following local anesthesia in a physician's clinic setting.

Group B will consist of 30 evaluable adults who require unilateral or bilateral tube insertion.

The iontophoresis system (IPS) will be used to facilitate anesthetic delivery to the tympanic membrane (TM). The lidocaine-based solution used for local anesthesia of the TM is Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine).

Subjects will receive active Tymbion iontophoresis and will have tubes placed using the TDS in all ears indicated for tube placement. The subject will rate the pain upon TDS tube insertion using the VAS, and the pain score will be compared to a performance goal.

Safety will be evaluated post procedure and at a follow-up visit.

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Adults at least 18 years of age at time of consent
Indication for tympanostomy tube insertion per Clinical Practice Guideline,or indicated for tympanostomy tube insertion due to barotrauma or Eustachian tube dysfunction per AAO-HNS Clinical Indicators.
Subject is able and willing to comply with the protocol and attend all study visits.
Subject is able and willing to provide informed consent.
Subject is able to read and understand English.

Exclusion Criteria by Ear:

Significantly atrophic, retracted or retraction pocket at location of tube placement, bimeric, monomeric or atelectatic tympanic membrane.
Perforated tympanic membrane.
Otitis externa.
Hemotympanum.
Damaged/denuded skin in the auditory canal.
Cerumen impaction resulting in a significant amount of cleaning required to visualize the tympanic membrane potentially causing abrasion or irritation to the external ear canal.
Notable ear discomfort experienced during audiologic or otoscopic examination.
Anatomy that precludes sufficient visualization of and access to the tympanic membrane.
Anatomy that necessitates tympanostomy tube placement in the posterior half of the tympanic membrane.

General Exclusion Criteria
Pregnant or lactating females
History of sensitivity or allergic reaction to lidocaine HCl, tetracaine, epinephrine, or any hypersensitivity to local anesthetics.
Familial history of insensitivity to lidocaine or other local anesthetics of the amide type.
Electrically sensitive medical support systems (eg, pacemakers, defibrillators, cochlear implants)
Other conditions that would preclude performing the study procedure including iontophoresis system ear plug incompatibility.
Health conditions that, in the opinion of the investigator, would present undue risk to the subject, based on device/anesthetic drug product label warnings and precautions